6L9.F ViewRay surges 2400.00% intraday on XETRA 30 Jan 2026: watch volume spike
ViewRay, Inc. (6L9.F stock) surged 2400.00% intraday on XETRA to €0.025 on 30 Jan 2026 as trade volume jumped to 3,500.00 shares, well above the 279.00 average. The move pushed the price from a €0.001 open to a €0.025 high, creating a high-volume breakout in a thinly traded name. Traders should note the extreme gap versus the 50-day average of €0.31916 and the 200-day average of €2.71739, indicating the move is volume-driven and not yet supported by sustained price structure. We examine drivers, valuation, and near-term scenarios for 6L9.F stock on XETRA in Germany.
Intraday price and volume snapshot for 6L9.F stock
ViewRay, Inc. (6L9.F) traded on XETRA at a high of €0.025 and a low of €0.001 today, with reported volume 3,500.00 versus an average volume of 279.00. The intraday change shows a +2400.00% swing from the previous close of €0.001. This is a classic high-volume mover profile: low float, large relative jump, and outsized relative volume. Traders should treat intraday volatility as elevated and expect wide bid-ask spreads.
Technical context and short-term outlook for 6L9.F stock
Price sits far below key moving averages: 50-day €0.31916 and 200-day €2.71739, so technical recovery would require several sustained volume sessions. Relative volume is 12.54, signalling outsized interest but short-lived liquidity. On a short-term basis, intraday support appears near €0.001 and immediate resistance at €0.030. Momentum traders may target quick scalps; position traders should wait for confirmation above €0.050 with higher volume.
Fundamentals, valuation and sector comparison for 6L9.F stock
ViewRay operates in Medical – Devices inside Healthcare. Key trailing metrics: EPS -0.55, P/E -0.05, price-to-sales 2.43, and book value per share €0.45514. Market cap on XETRA today is roughly €207,228,256.00 with 8,289,130,240.00 shares outstanding. Compared with the Healthcare sector average P/E of 33.27, ViewRay shows deep negative earnings and higher leverage with debt-to-equity 1.05. The company has a current ratio of 2.36, which supports short-term liquidity but margins remain negative at -105.01%. Investors should weigh device adoption potential against sustained negative profitability.
Meyka AI rating, model grade and 6L9.F stock analysis
Meyka AI rates 6L9.F with a score out of 100. Meyka AI rates 6L9.F with a score out of 100 Score: 57.52 | Grade: C+ | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. The grade reflects recovery potential in product demand but also the company’s negative EPS and stretched historic price performance. Readers should note this grade is informational and not investment advice.
Catalysts, risks and sector drivers for 6L9.F stock
Near-term catalysts include new MRIdian system orders, regulatory updates, and earnings announcements. The last reported earnings date was 2024-05-09; follow-up company news can move price rapidly in thin markets. Main risks are negative operating margins, long receivables cycle (DSO 147.79 days), and a year high of €4.600 that highlights prior price volatility. Sector trends in Healthcare show defensive flows; however, med-device names can decouple on product wins or clinical data.
Trading notes, price targets and strategy for 6L9.F stock
For intraday traders, set tight risk controls: initial stop below €0.001 and scale out on strength. Conservative near-term price target: €0.050. Bullish scenario target: €0.300 if volume and fundamentals re-rate. Bear case: reversion to €0.005 on failed momentum. Use position sizing given shares outstanding 8,289,130,240.00 and potential liquidity gaps. See company site for filings: ViewRay and our internal quote page: Meyka 6L9.F page.
Final Thoughts
Meyka AI’s forecast model projects €0.080 as a 12-month base case for ViewRay (6L9.F stock), implying +220.00% upside from the current €0.025 level, while a conservative near-term target is €0.050. Today’s intraday surge on XETRA was driven by a volume spike to 3,500.00, producing rapid price revaluation against weak moving averages. Fundamental metrics show negative EPS -0.55 and a P/E of -0.05, so any durable rally requires improving margins, clearer order momentum, or external re-rating. Meyka AI rates 6L9.F C+ (57.52) and classifies it as a HOLD under our model, reflecting mixed signals: device potential balanced by financial stress. Forecasts are model-based projections and not guarantees. Traders seeking exposure should prioritize risk limits, monitor order flow, and watch corporate updates and earnings dates closely before expanding positions.
FAQs
What drove the intraday move in 6L9.F stock today?
The intraday move was volume-driven: 6L9.F stock hit €0.025 on XETRA with 3,500.00 shares traded, far above the 279.00 average. Thin liquidity and potential news or order chatter often cause spikes in such small-cap med-device names.
What is Meyka AI’s rating and how should I use it for 6L9.F stock?
Meyka AI rates 6L9.F 57.52 (C+) with a HOLD suggestion. The grade blends sector, growth, metrics, and consensus. Use it as one data point alongside your own due diligence and risk controls.
What are realistic price targets and risks for 6L9.F stock?
Meyka suggests a near-term target €0.050 and a 12-month base-case €0.080, implying upside but with high volatility. Main risks: negative EPS -0.55, long receivables, and thin intraday liquidity that can cause sharp reversals.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
